AA
PACB icon

ALPS Advisors’s Pacific Biosciences PACB Stock Holding History

ALPS Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,557
Closed -$423K – 951
2021
Q3 		$423K Sell
16,557
-3,605
-18% -$107K ﹤0.01% 520
2021
Q2 		$705K Sell
20,162
-722
-3% -$21K 0.01% 469
2021
Q1 		$696K Sell
20,884
-5,046
-19% -$177K 0.01% 448
2020
Q4 		$673K Sell
25,930
-43,186
-62% -$734K 0.01% 439
2020
Q3 		$682K Sell
69,116
-40,457
-37% -$233K 0.01% 390
2020
Q2 		$378K Buy
+109,573
New +$373K 0.01% 501

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ALPS Advisors's PACB Position: Q4 2021 in Review

ALPS Advisors sold out of Pacific Biosciences (PACB) in Q4 2021, closing a stake of 16,557 shares — an estimated $423K sold.

ALPS Advisors first reported a position in PACB in Q2 2020 and held it in 6 quarters. The position peaked at $705K in Q2 2021. 256 funds tracked by Wall St. Rank hold PACB as of Q4 2021.

  • ALPS Advisors reported no remaining Pacific Biosciences position as of Q4 2021 after selling out during the quarter.
  • ALPS Advisors sold 16,557 Pacific Biosciences shares in Q4 2021, an estimated $423K.
  • ALPS Advisors first reported a position in Pacific Biosciences in Q2 2020 and held it in 6 quarters.
  • ALPS Advisors's Pacific Biosciences position peaked at $705K in Q2 2021.
  • 256 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.